VA to cover Eisai's new Alzheimer's drug after declining to cover Aduhelm

The Veterans Health Administration will cover Eisai and Biogen’s new Alzheimer’s drug Leqembi (lecanemab), reversing on an earlier decision to not pay for veterans to access Biogen’s other amyloid-targeted drug Aduhelm (aducanumab).